| Community-Acquired Pneumonia
Baxdela vs Nuzyra
Side-by-side clinical, coverage, and cost comparison for community-acquired pneumonia.Deep comparison between: Baxdela vs Nuzyra with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNuzyra has a higher rate of injection site reactions vs Baxdela based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Nuzyra but not Baxdela, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Baxdela
Nuzyra
At A Glance
IV infusion or Oral
Every 12 hours
Fluoroquinolone antibacterial
IV infusion or Oral
Once daily
Aminomethylcycline (tetracycline class)
Indications
- Acute bacterial skin and skin structure infection
- Community-Acquired Pneumonia
- Community-Acquired Pneumonia
- Skin Diseases, Bacterial
Dosing
Acute bacterial skin and skin structure infection 300 mg IV infusion every 12 hours over 60 minutes, or 450 mg orally every 12 hours, for 5-14 days; IV dose reduced to 200 mg every 12 hours in patients with eGFR 15-29 mL/min/1.73m2.
Community-Acquired Pneumonia 300 mg IV infusion every 12 hours over 60 minutes, or 450 mg orally every 12 hours, for 5-10 days; IV dose reduced to 200 mg every 12 hours in patients with eGFR 15-29 mL/min/1.73m2.
Community-Acquired Pneumonia Loading: IV 200 mg over 60 min or IV 100 mg over 30 min twice or Oral 300 mg twice on Day 1; Maintenance: IV 100 mg over 30 min once daily or Oral 300 mg once daily; duration 7 to 14 days.
Skin Diseases, Bacterial Loading: IV 200 mg over 60 min or IV 100 mg over 30 min twice on Day 1 or Oral 450 mg once daily on Days 1 and 2; Maintenance: IV 100 mg over 30 min once daily or Oral 300 mg once daily; duration 7 to 14 days.
Contraindications
- Known hypersensitivity to delafloxacin, any fluoroquinolone antibacterial, or any component of BAXDELA
- Known hypersensitivity to omadacycline, tetracycline class antibacterial drugs, or any excipient
Adverse Reactions
Most common (>=2%) Nausea, diarrhea, headache, transaminase elevations, vomiting
Serious Tendinitis and tendon rupture, peripheral neuropathy, CNS effects, hypersensitivity reactions, Clostridioides difficile-associated diarrhea, blood glucose disturbances
Most common (>=2%) In CABP: ALT increased, hypertension, GGT increased, insomnia, vomiting, constipation, nausea, AST increased, headache. In ABSSSI: nausea, vomiting, infusion site reactions, ALT increased, AST increased, headache, diarrhea.
Serious Mortality imbalance in CABP patients (2% vs 1% comparator); tooth development effects and enamel hypoplasia; inhibition of bone growth; hypersensitivity reactions.
Pharmacology
Delafloxacin is a fluoroquinolone antibacterial that inhibits bacterial topoisomerase IV and DNA gyrase, enzymes required for bacterial DNA replication, transcription, repair, and recombination, exhibiting concentration-dependent bactericidal activity against gram-positive and gram-negative organisms.
Omadacycline is an aminomethylcycline antibacterial within the tetracycline class that binds to the 30S ribosomal subunit and blocks protein synthesis; it is generally bacteriostatic but may demonstrate bactericidal activity against some isolates of S. pneumoniae and H. influenzae.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Baxdela
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
Nuzyra
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Baxdela
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Nuzyra
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Baxdela
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Nuzyra
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Baxdela.
$15/fillfill
Nuzyra Copay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BaxdelaView full Baxdela profile
NuzyraView full Nuzyra profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.